4512
WAKAMOTO PHARMACEUTICAL CO.,LTD.
わかもと製薬
- Industry
- Pharmaceutical
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2022
8,383,145
Mar 2023
8,660,379
Mar 2024
7,738,426
Mar 2025
7,789,462
Mar 2026
9,906,841
Operating profit(thousand JPY)
Mar 2022
-13,386
Mar 2023
141,467
Mar 2024
-195,511
Mar 2025
-457,796
Mar 2026
255,542
Operating profit margin(%)
Mar 2022
-0.16
Mar 2023
1.63
Mar 2024
-2.53
Mar 2025
-5.88
Mar 2026
2.58
Profit before tax(thousand JPY)
Mar 2022
284,858
Mar 2023
211,574
Mar 2024
158,854
Mar 2025
7,456
Mar 2026
256,396
Profit(thousand JPY)
Mar 2022
238,543
Mar 2023
138,256
Mar 2024
108,959
Mar 2025
64,440
Mar 2026
227,215
Total assets(thousand JPY)
Mar 2022
14,953,435
Mar 2023
15,711,553
Mar 2024
15,421,054
Mar 2025
15,002,709
Mar 2026
16,499,607
Cash and cash equivalents(thousand JPY)
Mar 2022
3,231,889
Mar 2023
3,879,325
Mar 2024
3,664,647
Mar 2025
2,954,759
Mar 2026
2,006,175
Cash flows from operating activities(thousand JPY)
Mar 2022
339,174
Mar 2023
631,920
Mar 2024
-107,338
Mar 2025
-592,454
Mar 2026
-486,912
Cash flows from investing activities(thousand JPY)
Mar 2022
50,572
Mar 2023
17,131
Mar 2024
-2,352
Mar 2025
-13,498
Mar 2026
-657,556
Cash flows from financing activities(thousand JPY)
Mar 2022
-1,620
Mar 2023
-1,615
Mar 2024
-104,986
Mar 2025
-103,935
Mar 2026
195,885
Return on equity(%)
Mar 2022
2.09
Mar 2023
1.18
Mar 2024
0.91
Mar 2025
0.55
Mar 2026
1.92
Equity ratio(%)
Mar 2022
76.77
Mar 2023
75.78
Mar 2024
77.98
Mar 2025
77.39
Mar 2026
72.78
Earnings per share(JPY per share)
Mar 2022
6.87
Mar 2023
3.98
Mar 2024
3.13
Mar 2025
1.85
Mar 2026
6.54
Net assets per share(JPY per share)
Mar 2022
330.79
Mar 2023
343.06
Mar 2024
346.5
Mar 2025
334.53
Mar 2026
346
Dividend per share(JPY per share)
Mar 2022
0
Mar 2023
3
Mar 2024
3
Mar 2025
3
Mar 2026
3.5
Payout ratio(%)
Mar 2022
0
Mar 2023
75.38
Mar 2024
95.85
Mar 2025
162.16
Mar 2026
53.52
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.